Latisse was introduced in the first quarter of 2009 by Allergan as the first drug to receive FDA approval for eyelash growth. Latisse is a solution of bimatoprost, the active component of the glaucoma medication Lumigan. According to Allergan, noticeable eyelash growth occurs within 16 weeks. Growth is reported to occur primarily on the upper eyelashes. In addition, the past decade has seen the rapid increase in the development of eyelash conditioners. These conditioners are designed to increase the health and length of lashes. Many utilize seed extract, minerals, and other chemicals to achieve these results.